Antibiotics

Antibiotics are chemical substances that selectively kill or inhibit the growth of bacteria, forming a cornerstone of modern medicine. Before their advent, bacterial infections such as pneumonia, tuberculosis, and wound sepsis were leading causes of death. The concept of a 'magic bullet' that could target pathogens without harming the host was championed by Paul Ehrlich, whose systematic screening of arsenic compounds led to the development of arsphenamine. In 1910, Ehrlich and his assistant Sahachiro Hata introduced arsphenamine under the trade name Salvarsan as the first effective treatment for syphilis, marking the birth of modern chemotherapy.

The next major advance came with the sulfonamide drugs. In 1935, Gerhard Domagk, a researcher at Bayer, published his findings that the red dye Prontosil protected mice against lethal streptococcal infection. Prontosil and its active breakdown product, sulfanilamide, were the first broad‑spectrum antibacterial agents available to clinicians. For this discovery, Domagk was awarded the Nobel Prize in Physiology or Medicine in 1939, although the Nazi regime forced him to decline the honour until after the war.

Alexander Fleming’s serendipitous observation in 1928—that a mould contaminating a petri dish lysed colonies of Staphylococcus—led to the identification of penicillin. However, the labile substance was difficult to isolate and produce in sufficient quantity. It was not until the late 1930s that Howard Florey, Ernst Chain, and Norman Heatley at the University of Oxford developed a reliable purification method. With the outbreak of World War II, the urgent need for a treatment of infected wounds spurred a massive Anglo‑American collaborative effort; by 1944, penicillin was being mass‑produced, significantly reducing battlefield mortality and ushering in the antibiotic era.

The success of penicillin triggered an intensive search for new natural antibiotics. Selman Waksman’s systematic screening of soil actinomycetes yielded streptomycin in 1943, the first drug effective against tuberculosis. The following two decades—often called the golden age of antibiotic discovery—saw the introduction of tetracyclines, chloramphenicol, macrolides, aminoglycosides, and cephalosporins, among others. Most of these agents were derived from soil‑dwelling bacteria and fungi, suggesting that the microbial world was a vast reservoir of chemical defence compounds.

Antibiotics exert their effects through a limited number of mechanisms: inhibition of cell wall synthesis (penicillins, cephalosporins), disruption of protein synthesis (tetracyclines, macrolides, aminoglycosides), interference with nucleic acid replication (fluoroquinolones), or blockade of essential metabolic pathways (sulfonamides, trimethoprim). Their selective toxicity relies on structural and metabolic differences between bacterial and host cells.

Almost as soon as antibiotics entered clinical use, bacteria began to develop resistance. Genes conferring resistance—coding for enzymes that degrade the drug, modify its target site, or pump it out of the cell—spread rapidly via horizontal gene transfer. The widespread and often indiscriminate use of antibiotics in human medicine, veterinary practice, and agriculture has accelerated this process. By the late 20th century, multi‑drug‑resistant strains of Staphylococcus aureus, Mycobacterium tuberculosis, and enteric Gram‑negative pathogens had become a serious global health threat. Today, antimicrobial resistance is ranked among the top public health challenges by the World Health Organization, and the pipeline for new antibiotics has slowed to a trickle, prompting calls for more prudent stewardship and novel therapeutic strategies.

The legacy of antibiotics is profound: life expectancy increased, surgical procedures became routine, and the terror of infectious disease diminished. Yet their future effectiveness depends on a delicate balance between innovation and conservation, a challenge that will define the next chapter in the history of medicine.